Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors

4 Apr 2022

Abstract excerpt

Pharmacological treatment of Duchenne muscular dystrophy (DMD) with histone deacetylase inhibitors (HDACi) is currently being tested in clinical trials; however, pre-clinical studies indicated that the beneficial effects of HDACi are restricted to early stages of disease. We show that FAPs from late-stage mdx mice exhibit aberrant HDAC activity and genome-wide alterations of histone acetylation that are not fully...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GDF15 and Related Biomarkers
Share to Histone Deacetylase Inhibitors Research
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35383427
DOI: 10.15252/embr.202254721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitorsPMID 35383427Read ↗

Partial resistance to HDAC inhibitors in FAPs of dystrophic muscles at late stages of disease is associated to epigenetic and transcriptional features of cellular senescenceSemantic proximity Read ↗

Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic DiseasesSemantic proximity Read ↗

Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.Semantic proximity Read ↗

Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophySemantic proximity Read ↗

Histone modifications in Duchenne muscular dystrophy: pathogenesis insights and therapeutic implications.Semantic proximity Read ↗

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular DystrophiesSemantic proximity Read ↗

Histone acetyltransferase inhibition rescues differentiation of emerin-deficient myogenic progenitorsSemantic proximity Read ↗

Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophySemantic proximity Read ↗

Defective plasticity in dermatomyositis patients muscle stem cells is associated with sustained intrinsic inflammatory signaling and disruption of the histone H3.3 chromatin loading pathwaySemantic proximity Read ↗

Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapiesSemantic proximity Read ↗

Role of Cdkn2a in the Emery-Dreifuss Muscular Dystrophy Cardiac Phenotype.Semantic proximity Read ↗

Epigenetic regulation of skeletal muscle development and differentiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.